Microba Life Sciences Past Earnings Performance
Past criteria checks 0/6
Microba Life Sciences's earnings have been declining at an average annual rate of -23.1%, while the Healthcare industry saw earnings growing at 1.5% annually. Revenues have been growing at an average rate of 40.9% per year.
Key information
-23.1%
Earnings growth rate
0.8%
EPS growth rate
| Healthcare Industry Growth | 2.4% |
| Revenue growth rate | 40.9% |
| Return on equity | -37.5% |
| Net Margin | -282.6% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Microba Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -18 | 11 | 13 |
| 30 Sep 23 | 6 | -16 | 10 | 11 |
| 30 Jun 23 | 5 | -13 | 10 | 9 |
| 31 Mar 23 | 5 | -12 | 10 | 8 |
| 31 Dec 22 | 5 | -11 | 10 | 6 |
| 30 Sep 22 | 5 | -11 | 10 | 6 |
| 30 Jun 22 | 5 | -11 | 10 | 5 |
| 31 Mar 22 | 4 | -11 | 9 | 5 |
| 31 Dec 21 | 4 | -11 | 9 | 4 |
| 30 Sep 21 | 4 | -9 | 8 | 3 |
| 30 Jun 21 | 4 | -8 | 7 | 2 |
| 30 Jun 20 | 3 | -7 | 7 | 0 |
| 30 Jun 19 | 2 | -5 | 4 | 0 |
Quality Earnings: MAP is currently unprofitable.
Growing Profit Margin: MAP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAP is unprofitable, and losses have increased over the past 5 years at a rate of 23.1% per year.
Accelerating Growth: Unable to compare MAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MAP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-19.1%).
Return on Equity
High ROE: MAP has a negative Return on Equity (-37.54%), as it is currently unprofitable.